Based on the data that the SARS coronavirus has generated up till now, scientists from Utrect University in the Netherlands in collaboration with Erasmus Medical Centre and the company Harbour BioMed discovered an antibody that prevents the coronavirus from infecting human cells.
The research is still in its infancy but could lead to the development of new treatments for the dreaded Corona Virus. The base of the new antibody was generated applying Harbour BioMed’s H2L2 transgenic mouse technology, in simple words, they used a genetically engineered to contain human genes, allowing researchers to produce “human” antibodies without testing them on humans.
The info must be taken with a grain of salt, seeing that “the groundbreaking” research is a potential method of counteracting the COVID-19 virus, and, as the teams stated, the antibody might prevent other SARS viruses from infecting the human body, blocking it from infecting human cells.
According to a peer-reviewed study published on Monday in the journal Nature Communications, the tests on cultured human cells lead the researchers to identify and discover one specific protein that binds to a specific part of both SARS and the virus causing COVID-19.
Testing their collection of antibodies on cultured human cells, researchers discovered one which binds to a specific part which is present in both SARS and the virus causing COVID-19.
This may lead to a cure sooner then we think if the research proves to be fruitful and the antibody does not affect other parts of the human anatomy.
Dr. Berend-Jan Bosch, one of the co-authors of the study said that the new antibody has the potential to radically modify the development of the infection in a host, maintain virus removal or shield an uninfected individual that has never been exposed to the virus.
A fully-human antibody is distinct from traditional curative antibodies, most of them are often first manifested in other species before being adapted for the human physiology.
Another study’s other co-lead author, Dr. Frank Grosveld, stated that the data provided by the new antibody might prove to be a “strong foundation for additional research” leading to a new COVID-19 treatment, or even a cure. This is because the antibody used in the research is “fully human”, and allows the development to move more rapidly, and of course, reduces any potential of immune-related side effects.
Follow TechTheLead on Google News to get the news first.
